title: Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML).
authors.forename: Apostolos
authors.initials: A
authors.lastname: Tsapas
authors.forename: Efthymia
authors.initials: E
authors.lastname: Vlachaki
authors.forename: Maria
authors.initials: M
authors.lastname: Sarigianni
authors.forename: Filippos
authors.initials: F
authors.lastname: Klonizakis
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Paletas
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D007333:Insulin Resistance / Q000502:physiology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases